![Thomas Meier](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Thomas Meier
Fundador en SANTHERA PHARMACEUTICALS HOLDING AG .
Fortuna: 34 003 $ al 31/05/2024
Perfil
Dr. Thomas Meier is a Chairman at Santhera Pharmaceuticals Holding AG and a Managing Partner at Viopas Venture Consulting GmbH.
He is on the Board of Directors at Onconetix, Inc., Visgenx, Inc. and Novaremed AG.
Dr. Meier was previously employed as a Chief Executive Officer by MyoContract AG and a Chairman by PharmaBiome AG.
He received his graduate degree from the University of Basel and a doctorate degree from the University of Basel.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
31/12/2023 | 3 108 ( 0.02% ) | 34 003 $ | 31/05/2024 |
Cargos activos de Thomas Meier
Empresas | Cargo | Inicio |
---|---|---|
SANTHERA PHARMACEUTICALS HOLDING AG | Fundador | 07/09/2004 |
ONCONETIX, INC. | Director/Miembro de la Junta | 06/02/2024 |
Novaremed AG
![]() Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | Director/Miembro de la Junta | 01/05/2020 |
Viopas Venture Consulting GmbH
![]() Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland. | Corporate Officer/Principal | - |
Visgenx, Inc.
![]() Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | Director/Miembro de la Junta | 01/01/2022 |
Antiguos cargos conocidos de Thomas Meier.
Empresas | Cargo | Fin |
---|---|---|
PharmaBiome AG
![]() PharmaBiome AG Miscellaneous Commercial ServicesCommercial Services PharmaBiome AG specializes in isolation, characterization, and technology of novel intestinal microbes. It develops and produces microbiome therapies to treat intestinal diseases. The company was founded by Tomas de Wouters and is headquartered in Zurich, Switzerland. | Presidente | 01/01/2021 |
MyoContract AG | Director Ejecutivo | 01/01/2004 |
Formación de Thomas Meier.
University of Basel | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
SANTHERA PHARMACEUTICALS HOLDING AG | Health Technology |
ONCONETIX, INC. | Health Technology |
Empresas privadas | 5 |
---|---|
MyoContract AG | Health Technology |
Novaremed AG
![]() Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | Health Technology |
PharmaBiome AG
![]() PharmaBiome AG Miscellaneous Commercial ServicesCommercial Services PharmaBiome AG specializes in isolation, characterization, and technology of novel intestinal microbes. It develops and produces microbiome therapies to treat intestinal diseases. The company was founded by Tomas de Wouters and is headquartered in Zurich, Switzerland. | Commercial Services |
Viopas Venture Consulting GmbH
![]() Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland. | Finance |
Visgenx, Inc.
![]() Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Thomas Meier